February 19, 2008 – The first CE certified Nobori Drug-Eluting Coronary Stent System was successfully implanted in Europe, as Terumo Corp. is poised to expand the product from spring 2008 to more than 20 countries in Europe, Asia, New Zealand and Africa.
The Nobori stent system is a stent (DES) with a bioresorbable polymer. The procedure was performed by Antonio Colombo, M.D., director of the Cardiac Catheterization Laboratory at Columbus Hospital and San Raffaele Hospital, Milan, Italy, in a live case transmission during JIM congress held in Rome.
"I successfully finished this highly tortuous right coronary case using Nobori Drug-Eluting Coronary Stent System. It looks very promising. I look forward to seeing this new generation stent in daily use." said Dr. Colombo.
The launch of Nobori stent will include a comprehensive clinical program to characterize the stent’s long-term safety and efficacy in a variety of patient populations. The program will enroll more than 5,000 patients in randomized trials and post-marketing registry.
For more information: www.terumo.com
July 02, 2024 
